The phase 3 HER2CLIMB-02 trial demonstrated significant prolongation of progression-free survival with tucatinib plus ado-trastuzumab emtansine combination therapy in patients with previously treated HER2+ metastatic breast cancer (MBC). Read More ›

This correlative study identified significant differences in the expression of estrogen receptor between tumor tissue and circulating tumor cell analyses in metastatic breast cancer (MBC). Read More ›

In a prospective HER2+ metastatic breast cancer (MBC) cohort, one-third of patients achieved exceptional response to first-line HER2-targeted therapy, who presented more frequently with de novo disease and HER2 immunohistochemistry 3+ tumors. Read More ›

Updated overall survival analysis data from a retrospective chart review showed promising efficacy of T-DXd therapy in patients with HER2+ metastatic breast cancer (MBC) with long-term and heavily pretreated brain metastases and/or leptomeningeal carcinomatosis. Read More ›

The phase 3, randomized, double-blind HER2CLIMB-05 study (NCT05132582) is evaluating the addition of tucatinib to trastuzumab plus pertuzumab as maintenance therapy in patients with HER2+ metastatic breast cancer (MBC). Read More ›

Findings of a quality improvement initiative identified several gaps in guideline-aligned patient-centered care in HER2+ metastatic breast cancer (MBC), providing opportunities to implement action plans that improve patient outcomes in the community setting. Read More ›

Hypothesis-generating findings of a retrospective study in a small cohort of tucatinib-treated patients indicates a potential correlation between KMT2C mutations and unfavorable clinical outcomes. Read More ›

Real-world data from a large, prospective, single-institution cohort of older patients with metastatic breast cancer (MBC) indicated poor survival outcomes with increasing age, particularly for those aged >80 years. Read More ›

Exploratory data indicate that an immunohistochemistry (IHC) score of 3+ is less likely to be associated with lymph node and visceral metastases in patients with HER2+ metastatic breast cancer (MBC), and that site of metastasis has prognostic value in both the IHC 3+ and IHC 2+ subgroups. Read More ›

Results of a single-institution chart review indicated that central nervous system (CNS) involvement directly correlated with CNS-related death in patients with metastatic breast cancer (MBC), with greatest risk in those with leptomeningeal disease. Read More ›

Page 1 of 2

Conference Correspondent Coverage is Brought to You by the Publishers of:
Oncology Practice Management
Value-Based Cancer Care

Learn more about our family of publications.

View Our Publications